Seeding trials, clinical studies conducted by pharmaceutical companies for marketing purposes, have rarely been described. Using documents produced during the gabapentin (Neurontin) marketing, sales practices, and product liability litigation, the investigators reviewed all documents related to the clinical trial Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) to determine the extent of marketing involvement in its planning and implementation. Documents demonstrated that STEPS was a seeding trial posing as a legitimate scientific study. The trial itself, not trial results, was part of a marketing strategy used to promote gabapentin and increase prescribing among investigators without informing trial patients or investigators. Marketing was extensively involved in its planning and implementation and rates and dosages of gabapentin prescribing among STEPS investigators were examined to determine the impact of investigator participation in the STEPS trial. These ethical breaches in clinical trial conduct and steps to prevent seeding trials from taking place in the future are discussed.